Safety Alerts & Recalls
What does this mean?
Although there is conflicting information about whether abacavir treatment increases the risk of heart attack, the FDA’s recent review found no difference in heart attack events between patients who received abacavir and those who did not.
If you take abacavir (Ziagen) or a product containing abacavir (Trizivir or Epzicom), you should continue to take your medicine as directed by your healthcare professional. Please discuss any questions or concerns about abacavir with your healthcare professional.
FDA Review of Abacavir Finds No Increased Risk of Heart Attack
The Food and Drug Administration (FDA) updated the public about an ongoing safety review of abacavir and a possible increased risk of heart attack (also known as myocardial infarction or MI) seen in some research studies, but not in others. The FDA reviewed 26 randomized clinical trials, and did not find an increased risk of heart attack associated with the use of abacavir. The FDA will continue to communicate any new safety information to the public as it becomes available.
Abacavir is an antiviral medication used in combination with other antiretroviral drugs for the treatment of HIV-1 infection. Abacavir is sold under the brand name Ziagen and is also sold in combination with other antiretroviral drugs under the names Trizivir and Epzicom.
For more information, please visit: more information here